Articles tagged "Co-stimulation"

2021 American Transplant Congress
Cognition After Belatacept Conversion (CAB) Trial
W. Asch¹, K. Belfield², V. Do², E. Cohen¹
¹Yale University, New Haven, CT, ²Yale New Haven Hospital, New Haven, CT
*Purpose: Extensive adverse effect profiles including neurotoxicity, manifesting as short-term memory loss, make CNIs less desirable despite their efficacy preventing acute rejection and increasing graft…
2021 American Transplant Congress
Anti-CD272 Antibody (6B2) Generated Foxp3⁺Regulatory T Cells and Suppressed Donor Specific Antibody in Murine Cardiac Transplant Model
Y. Yamamoto¹, M. Uchiyama², K. Uchida³, H. Yagita³, M. Niimi¹
¹Department of Surgery, Teikyo University, Tokyo, Japan, ²Department of Cardiovascular Surgery, Teikyo University, Tokyo, Japan, ³Juntendo University, Tokyo, Japan
*Purpose: The co-inhibitory receptor B and T lymphocyte attenuator (BTLA; CD272) has been implicated in the regulation of autoimmune and may potentially play an important…
2021 American Transplant Congress
Desensitization Using Costimulatory Blockade and Bortezomib to Prevent DSA Formation and Rejection in Reconstructive Transplantation
B. Oh¹, F. Messner², Y. Guo¹, G. Brandacher¹
¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Department of Visceral, Transplant and Thoracic Surgery, University of Innsbruck, Innsbruck, Austria
*Purpose: Sensitization in form of donor-specific antibodies (DSA) and subsequent antibody-mediated rejection constitute some of the greatest risk factors for allograft rejection and long-term graft…
2021 American Transplant Congress
Belatacept Pharmacokinetics in Patients with and without Infection
A. Bickenbach¹, M. McGowan¹, B. Miyagawa², T. Mizuno², A. Shields³, A. Christianson¹, P. West-Thielke⁴, J. Leone⁵, E. Woodle¹, D. Kaufman⁶, A. Wiseman⁷, A. Vinks², R. Alloway¹
¹U Cincinnati, Cincinnati, OH, ²Cincinnati Children's Med Center, Cincinnati, OH, ³Christ Hospital, Cincinnati, OH, ⁴UIC, Chicago, IL, ⁵Tampa Gen, Tampa, FL, ⁶U Wisconsin, Madison, WI, ⁷Centura Transplant, Denver, CO
*Purpose: Two belatacept(BELA) fixed mg/kg dosing regimens, less intense(LI) and more intense(MI) were compared. The LI regimen was approved due to the higher risk profile…
2021 American Transplant Congress
Belatacept Pharmacokinetic Analysis Comparing Belatacept Early Steroid Withdrawal Trial (BEST) with Benefit and Benefit-ext Trials
A. Bickenbach¹, M. McGowan¹, B. Miyagawa², T. Mizuno², A. Shields³, A. Christianson¹, P. West-Thielke⁴, J. Leone⁵, E. Woodle¹, D. Kaufman⁶, A. Wiseman⁷, A. Matas⁸, A. Vinks²
¹U Cincinnati, Cincinnati, OH, ²Cincinnati Childrens Med Center, Cincinnati, OH, ³Christ Hospital, Cincinnati, OH, ⁴UIC, Chicago, IL, ⁵Tampa Gen, Tampa, FL, ⁶U Wisconsin, Madison, WI, ⁷Centura Transplant, Denver, CO, ⁸U Minnesota, Minneapolis, MN
*Purpose: Belatacept(BELA) pharmacokinetic(PK) studies informed dosing in phase 3 studies where fixed mg/kg dosing compared a less intense(LI) and more intense(MI) regimen. LI was preferred…
2021 American Transplant Congress
Belatacept Conversion in Elderly Renal Transplant Recipients
M. Durst¹, D. Felix¹, M. Jorgenson¹, J. Descourouez¹, B. C. Astor², D. Mandelbrot²
¹UW Health, Madison, WI, ²University of Wisconsin School of Medicine and Public Health, Madison, WI
*Purpose: Describe the impact of conversion from a calcineurin inhibitor (CNI) based immunosuppressive regimen to belatacept in elderly renal transplant recipients.*Methods: Adult renal transplant patients…
2021 American Transplant Congress
Infectious Complications After Belatacept Conversion in Kidney Transplant
J. E. Marvin¹, D. Amenyedor¹, M. M. Azar², K. Belfield¹, V. Do¹, R. Formica³, E. Cohen¹
¹Pharmacy, Yale New Haven Hospital, New Haven, CT, ²Section of Infectious Diseases, Yale School of Medicine, New Haven, CT, ³Section of Nephrology, Yale School of Medicine, New Haven, CT
*Purpose: Tacrolimus (tac), a calcineurin inhibitor, is associated with multiple adverse effects when used for immunosuppression following kidney transplant (KT). Belatacept (bela) is a monoclonal…
2021 American Transplant Congress
A Comparison of Belatacept Conversion Regimens from Calcineurin Inhibitor-Based Immunosuppression
E. Huang, A. Vo, A. Peng, R. Najjar, S. Sethi, S. Jordan
Cedars-Sinai Medical Center, Los Angeles, CA
*Purpose: Outcomes with varying belatacept conversion protocols from calcineurin inhibitor (CNI)-based immunosuppression have been published but no standard protocol has been established. Beginning in 2012,…
2021 American Transplant Congress
Renal Preservation with Belatacept-Based versus Everolimus-Based Immunosuppression in Lung Transplant Recipients
E. Sartain¹, K. Schoeppler¹, B. Crowther¹, J. Smith², A. Gray²
¹University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, ²Department of Medicine, Division of Pulmonary Sciences and Critical Care, University of Colorado, Denver, CO
*Purpose: Renal dysfunction is one of the most common long-term complications among lung transplant recipients (LTRs). Calcineurin-inhibitor (CNI) nephrotoxicity is a recognized contributor to renal…
2021 American Transplant Congress
Tolerability of De Novo and Conversion Belatacept Regimens in Kidney Transplantation
T. Le¹, J. Shoji², J. Phillips¹, D. Quan¹
¹Pharmaceutical Services, UCSF Medical Center, San Francisco, CA, ²Transplant Nephrology, UCSF Medical Center, San Francisco, CA
*Purpose: Belatacept, a selective T lymphocyte co-stimulation blocker, has been shown to be a safe and effective maintenance therapy for immunosuppression. We investigated the long-term…

« Previous Page
1
…
3
4
5
6
7
…
30
Next Page »